Is AIM ImmunoTech Inc (AIM) Stock a Good Buy in Biotechnology

Tuesday, July 7, 2020 10:44 AM | InvestorsObserver Analysts

AIM ImmunoTech Inc (AIM) is near the top in its industry group according to InvestorsObserver. AIM gets an overall rating of 70. That means it scores higher than 70 percent of stocks. AIM ImmunoTech Inc gets a 78 rank in the Biotechnology industry. Biotechnology is number 11 out of 148 industries.

Overall Score - 70
AIM has an Overall Score of 70. Find out what this means to you and get the rest of the rankings on AIM!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 70 would rank higher than 70 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With AIM ImmunoTech Inc Stock Today?

AIM ImmunoTech Inc (AIM) stock is trading at $2.43 as of 10:41 AM on Tuesday, Jul 7, a loss of -$0.07, or -2.8% from the previous closing price of $2.50. The stock has traded between $2.38 and $2.51 so far today. Volume today is light. So far 706,817 shares have traded compared to average volume of 3,943,284 shares.

To see InvestorsObserver's Sentiment Score for AIM ImmunoTech Inc click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Sector Update: Health Care

Nasdaq Leading Major Indexes Higher in Late Monday Trading

Will TherapeuticsMD Inc (TXMD) Beat the Rest of the Stocks in the Healthcare Sector?

Is Ibio Inc (IBIO) A Winner in the Healthcare Sector?

Related Companies